Stocks to Watch: Intel, Vanda Pharmaceuticals, OneMedNet

By Ben Glickman

Intel released restated results for the last three years to break out its foundry business, revealing the segment generated an operating loss of about $7 billion in 2023. The business's sales from other parts of Intel, or internal revenue, fell sharply to $18 billion that same year. Shares fell 3.8%, to $42.26, after hours.

Vanda Pharmaceuticals said it had received regulatory approval for Fanapt to treat manic or mixed episodes linked to bipolar I disorder in adults. The treatment has been used in adults with schizophrenia for years, but the company said the new indication would increase Fanapt's commercial opportunity. Shares surged 31%, to $5.13, in late trading.

OneMedNet said it had secured up to $4.54 million in cash through a securities purchase agreement with an institutional investor. The company also announced Aaron Green as its next chief executive as predecessor Paul Casey retires. Shares rose 44%, to $1.14, in the post-market session.

Write to Ben Glickman at ben.glickman@wsj.com

(END) Dow Jones Newswires

April 02, 2024 19:54 ET (23:54 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.